바이러스성 관절염 백신 시장 보고서(2026년)

A viral arthritis vaccine is a preventive immunization developed to trigger immune protection against viruses that cause arthritis, including Chikungunya virus, Ross River virus, and other arthritogenic viruses. It works to lower infection risk, reduce disease severity, and prevent long-term joint complications by blocking viral entry and replication. It aims to prevent acute illness and chronic inflammatory arthritis while minimizing immune-related joint damage in exposed or high-risk populations.

The primary types of viral arthritis vaccines include viral arthritis vaccine, live, and viral arthritis vaccine, inactivated. Viral arthritis vaccine, live, refers to vaccines that employ a weakened form of the virus to stimulate immunity against viral arthritis. These vaccines target viruses such as chikungunya virus, rubella virus, parvovirus, and other viruses causing viral arthritis. They are applied across farms and individual use, and are administered to end users including hospitals and clinics, vaccination centers, homecare, and government programs.

Tariffs are affecting the viral arthritis vaccine market by increasing the cost of imported bioreactor equipment, cold chain systems, and specialized vaccine inputs. Higher duties on pharmaceutical manufacturing tools and raw materials are raising production and distribution costs. Regions dependent on imported vaccine production components are seeing higher capital and operating expenses. Advanced platform vaccines using specialized inputs are more exposed to tariff pressure. Finished vaccine demand remains strong despite cost shifts. At the same time, tariffs are encouraging domestic vaccine manufacturing capacity and local supply chains. This supports regional biotech producers and contract manufacturers.

The viral arthritis vaccine market research report is one of a series of new reports from The Business Research Company that provides viral arthritis vaccine market statistics, including viral arthritis vaccine industry global market size, regional shares, competitors with a viral arthritis vaccine market share, detailed viral arthritis vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the viral arthritis vaccine industry. This viral arthritis vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral arthritis vaccine market size has grown rapidly in recent years. It will grow from $6.66 billion in 2025 to $7.36 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to chikungunya outbreak history, vaccine platform advances, global immunization programs, zoonotic virus research, public health preparedness efforts.

The viral arthritis vaccine market size is expected to see rapid growth in the next few years. It will grow to $11.09 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to next generation vaccine platforms, emerging arbovirus threats, accelerated clinical trials, global travel related exposure, preventive immunization expansion. Major trends in the forecast period include mrna based viral arthritis vaccines, recombinant vector vaccine platforms, multivalent arthritogenic virus vaccines, rapid response vaccine design, adjuvanted immunogenic formulations.

A growing incidence of mosquito-borne viral infections is expected to propel the expansion of the viral arthritis vaccine market in the coming years. Mosquito-borne viral infections are diseases transmitted to humans via infected mosquito bites, including chikungunya, Zika, and dengue viruses, which can cause fever, joint pain, rashes, and, in some cases, long-term complications like viral arthritis. Their prevalence is increasing due to climate change, which creates warmer temperatures and altered rainfall patterns, expanding mosquito habitats and breeding seasons. Viral arthritis vaccines help mitigate mosquito-borne infections by preventing virus-related infection and disease progression, thereby reducing transmission risks and disease burden among populations. For instance, in 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, more than 7.6 million cases were reported globally by April, tripling the number recorded during the same period in 2023, with transmission continuing across over 90 countries. Therefore, the rising incidence of mosquito-borne viral infections is driving the viral arthritis vaccine market.

Leading companies operating in the viral arthritis vaccine market are focusing on advancing innovative vaccine candidates, such as live-attenuated and next-generation chikungunya vaccines, to address the growing need for effective prevention of viral-induced joint pain and long-term arthritic complications, particularly in vulnerable populations. Live-attenuated and next-generation chikungunya vaccines refer to advanced vaccine formulations designed to prevent chikungunya virus infection by eliciting strong and long-lasting immune responses, where live-attenuated vaccines use weakened forms of the virus to closely mimic natural infection and provide durable protection, and next-generation vaccines employ modern platforms such as viral vectors, recombinant proteins, or novel attenuation technologies to enhance safety, immunogenicity, and broader population applicability. For example, in June 2025, Bavarian Nordic A/S, a Denmark-based biotechnology company, initiated a Phase 3 clinical study of its chikungunya vaccine in children, aiming to expand protection to pediatric populations in endemic regions, where early-life exposure can lead to significant disease burden. The progression to late-stage clinical evaluation reflects growing confidence in the vaccine's safety and immunogenicity profile and underscores efforts to broaden age indications, strengthen population-level immunity, and reduce the long-term impact of chikungunya-associated viral arthritis globally.

In December 2024, Valneva SE, a France-based biotech firm, entered into a partnership with the Serum Institute of India for its single-shot chikungunya vaccine under an exclusive licensing agreement. Through this collaboration, the partners intend to increase access to the vaccine across Asia and support wider distribution to low- and middle-income countries, leveraging local manufacturing and regulatory capabilities. The Serum Institute of India is an India-based company specializing in producing and distributing affordable vaccines at large scale for public health markets worldwide.

Major companies operating in the viral arthritis vaccine market are Bavarian Nordic A/S, Serum Institute of India Private Limited, Valneva SE, Bharat Biotech International Limited, Panacea Biotec Ltd., The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd.

North America was the largest region in the viral arthritis vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral arthritis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the viral arthritis vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The viral arthritis vaccine market consists of sales of live-attenuated viral vaccines, inactivated viral vaccines, virus-like particle-based vaccines, recombinant subunit vaccines, messenger ribonucleic acid-based vaccines, and viral vector-based vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral Arthritis Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses viral arthritis vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral arthritis vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The viral arthritis vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Viral Arthritis Vaccine, Live; Viral Arthritis Vaccine, Inactivated
• 2) By Virus Targeted: Chikungunya Virus; Rubella Virus; Parvovirus; Other Viral Arthritis-Causing Viruses
• 3) By Application: Farms; Individual
• 4) By End-User: Hospitals And Clinics; Vaccination Centers; Homecare; Government Programs
• Subsegments:
• 1) By Viral Arthritis Vaccine, Live: Single Dose; Combination Dose; Recombinant Live Vaccine
• 2) By Viral Arthritis Vaccine, Inactivated: Whole Virus Inactivated Vaccine; Split Virus Inactivated Vaccine; Adjuvanted Inactivated Vaccine
• Companies Mentioned: Bavarian Nordic A/S; Serum Institute of India Private Limited; Valneva SE; Bharat Biotech International Limited; Panacea Biotec Ltd.; The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Viral Arthritis Vaccine Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Viral Arthritis Vaccine Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Viral Arthritis Vaccine Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Viral Arthritis Vaccine Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Sustainability, Climate Tech & Circular Economy
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Mrna Based Viral Arthritis Vaccines
  • 4.2.2 Recombinant Vector Vaccine Platforms
  • 4.2.3 Multivalent Arthritogenic Virus Vaccines
  • 4.2.4 Rapid Response Vaccine Design
  • 4.2.5 Adjuvanted Immunogenic Formulations

5. Viral Arthritis Vaccine Market Analysis Of End Use Industries

• 5.1 Hospitals And Clinics
• 5.2 Vaccination Centers
• 5.3 Government Immunization Programs
• 5.4 Public Health Agencies
• 5.5 Travel Health Centers

6. Viral Arthritis Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Viral Arthritis Vaccine Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Viral Arthritis Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Viral Arthritis Vaccine Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Viral Arthritis Vaccine Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Viral Arthritis Vaccine Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Viral Arthritis Vaccine Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Viral Arthritis Vaccine Market Segmentation

• 9.1. Global Viral Arthritis Vaccine Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Viral Arthritis Vaccine, Live, Viral Arthritis Vaccine, Inactivated
• 9.2. Global Viral Arthritis Vaccine Market, Segmentation By Virus Targeted, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chikungunya Virus, Rubella Virus, Parvovirus, Other Viral Arthritis-Causing Viruses
• 9.3. Global Viral Arthritis Vaccine Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Farms, Individual
• 9.4. Global Viral Arthritis Vaccine Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals And Clinics, Vaccination Centers, Homecare, Government Programs
• 9.5. Global Viral Arthritis Vaccine Market, Sub-Segmentation Of Viral Arthritis Vaccine, Live, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Single Dose, Combination Dose, Recombinant Live Vaccine
• 9.6. Global Viral Arthritis Vaccine Market, Sub-Segmentation Of Viral Arthritis Vaccine, Inactivated, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Whole Virus Inactivated Vaccine, Split Virus Inactivated Vaccine, Adjuvanted Inactivated Vaccine

10. Viral Arthritis Vaccine Market Regional And Country Analysis

• 10.1. Global Viral Arthritis Vaccine Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Viral Arthritis Vaccine Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Viral Arthritis Vaccine Market

• 11.1. Asia-Pacific Viral Arthritis Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Viral Arthritis Vaccine Market

• 12.1. China Viral Arthritis Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Viral Arthritis Vaccine Market

• 13.1. India Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Viral Arthritis Vaccine Market

• 14.1. Japan Viral Arthritis Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Viral Arthritis Vaccine Market

• 15.1. Australia Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Viral Arthritis Vaccine Market

• 16.1. Indonesia Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Viral Arthritis Vaccine Market

• 17.1. South Korea Viral Arthritis Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Viral Arthritis Vaccine Market

• 18.1. Taiwan Viral Arthritis Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Viral Arthritis Vaccine Market

• 19.1. South East Asia Viral Arthritis Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Viral Arthritis Vaccine Market

• 20.1. Western Europe Viral Arthritis Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Viral Arthritis Vaccine Market

• 21.1. UK Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Viral Arthritis Vaccine Market

• 22.1. Germany Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Viral Arthritis Vaccine Market

• 23.1. France Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Viral Arthritis Vaccine Market

• 24.1. Italy Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Viral Arthritis Vaccine Market

• 25.1. Spain Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Viral Arthritis Vaccine Market

• 26.1. Eastern Europe Viral Arthritis Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Viral Arthritis Vaccine Market

• 27.1. Russia Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Viral Arthritis Vaccine Market

• 28.1. North America Viral Arthritis Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Viral Arthritis Vaccine Market

• 29.1. USA Viral Arthritis Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Viral Arthritis Vaccine Market

• 30.1. Canada Viral Arthritis Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Viral Arthritis Vaccine Market

• 31.1. South America Viral Arthritis Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Viral Arthritis Vaccine Market

• 32.1. Brazil Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Viral Arthritis Vaccine Market

• 33.1. Middle East Viral Arthritis Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Viral Arthritis Vaccine Market

• 34.1. Africa Viral Arthritis Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Viral Arthritis Vaccine Market, Segmentation By Type, Segmentation By Virus Targeted, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Viral Arthritis Vaccine Market Regulatory and Investment Landscape

36. Viral Arthritis Vaccine Market Competitive Landscape And Company Profiles

• 36.1. Viral Arthritis Vaccine Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Viral Arthritis Vaccine Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Viral Arthritis Vaccine Market Company Profiles
  • 36.3.1. Bavarian Nordic A/S Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Serum Institute of India Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Valneva SE Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Bharat Biotech International Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Panacea Biotec Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Viral Arthritis Vaccine Market Other Major And Innovative Companies

• The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd.

38. Global Viral Arthritis Vaccine Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Viral Arthritis Vaccine Market

41. Viral Arthritis Vaccine Market High Potential Countries, Segments and Strategies

• 41.1 Viral Arthritis Vaccine Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Viral Arthritis Vaccine Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Viral Arthritis Vaccine Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer